Business
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical trials – – Oral and poster presentations feature first data presented from ABI-1179, expected to enter the clinic by the end of 2024 – SOUTH SAN FRANCISCO, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced new preclinical data from its investigational herpes simplex virus (HSV) portfolio featured in three presentations at the International Herpesvirus Workshop (IHW), taking place July 13-17, 2024, in Portland, Ore. “We are excited to present promising data from our HSV helicase-primase inhibitor candidates ABI-5366 and ABI-1179, which we are rapidly progressing to deliver on our mission of offering new, effective treatments for people living with chronic viral diseases,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “Current treatments for recurrent genital herpes often fall short in fully managing symptoms and preventing recurrences, and we are pleased with the potential of our HSV candidates to provide a different approach, as highlighted in the data presented at IHW. We continue to advance these candidates and look forward to sharing further updates with the herpesvirus community, including interim ABI-5366 Phase 1a first-in-human data expected in the third quarter of this year.” Approximately 50% of individuals with initial symptomatic genital herpes infection have three or more recurrences per year, including over four million people in the United States and France, Germany, Italy and Spain (collectively, the EU4), and the United Kingdom. While genital herpes can be caused by either HSV type 1 (HSV-1) or HSV type 2 (HSV-2), recurrences are more likely to be experienced by individuals infected by HSV-2. The current standard of care for recurrent genital herpes are nucleoside analogs; however, these are only partially effective in preventing recurrences. Assembly Bio’s HSV antiviral candidates target the HSV helicase-primase complex, an essential HSV enzyme complex with no host equivalent, and are design...